The goal of the Career Enhancement Program (CEP) is to enhance pancreatic cancer research by providing financial support and mentoring for investigators new to the field. The CEP will recruit both junior faculty and established investigators who are transitioning into pancreatic cancer research. Highly qualified individuals will receive awards that will help support their research in this field, with a major emphasis on translational research. The CEP will ensure that its new investigators are mentored by both a clinical and a laboratory scientist. The CEP will select awardees from the collaborating SPORE institutions and, as the program matures, from other appropriately qualified institutions. Financial support (salary, research supplies and tuition) will be provided for up to two years. The CEP will facilitate interactions between awardees and all members of the SPORE, emphasizing the basic and clinical science cross-fertilization that is essential to translational research. The Siteman Cancer Center, Washington University, and our collaborating SPORE institutions provide outstanding opportunities for career development in translational pancreatic cancer research. We have the broad research base, existing and continually evolving new collaborations, basic science, and clinical programs in pancreatic cancer, meaning we have the wiling mentors necessary to make the CEP a success. A CEP Advisory Committee of senior faculty has been established. William E. Gillanders, M.D., Director of the CEP, will chair the committee, and work with the SPORE leadership, project leaders and administrative staff to provide support to new investigators. Channing Der, Ph.D., will serve as the co-Director, bringing a wealth of expertise in basic science mentorship to the CEP. We will specifically seek out underrepresented minority faculty to participate in the program. Sarah Gehlert Ph.D. will assist with the recruitment, training, and retention of women, minorities, and disabled investigators in pancreatic cancer research. The CEP, along with the DRP, is specifically committed to the recruitment of minority investigators. To foster inter-SPORE collaborations, we have established collaborations with SPORE programs at the University of Nebraska Medical Center and Vanderbilt University Medical Center. This will encourage participation in the CEP programs at each of the SPORE institutions. The CEP will be open to all institutions participating in the SPORE. Intra-SPORE collaborations will also be facilitated with University of North Carolina, University of Rochester, and Johns Hopkins University, broadening the CEP applicant pool and helping to match the interests of junior investigators with local expertise and need.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA196510-05
Application #
9982231
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Pati, Maria Laura; Niso, Mauro; Spitzer, Dirk et al. (2018) Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (?2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors. Eur J Med Chem 144:359-371
Brauer, David G; Ohman, Kerri A; Jaques, David P et al. (2018) Surgeon Variation in Intraoperative Supply Cost for Pancreaticoduodenectomy: Is Intraoperative Supply Cost Associated with Outcomes? J Am Coll Surg 226:37-45.e1
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Nywening, Timothy M; Belt, Brian A; Cullinan, Darren R et al. (2018) Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut 67:1112-1123
Brenot, Audrey; Knolhoff, Brett L; DeNardo, David G et al. (2018) SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion. Oncogenesis 7:32
Meyer, Melissa A; Baer, John M; Knolhoff, Brett L et al. (2018) Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat Commun 9:1250
Meyer, Melissa A; DeNardo, David G (2018) Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1. Immunity 48:621-623
Jiang, Hongmei; Xu, Mai; Li, Lin et al. (2018) Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Mol Cancer Ther 17:2144-2155
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Zhang, Daoxiang; Li, Lin; Jiang, Hongmei et al. (2018) Tumor-Stroma IL1?-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. Cancer Res 78:1700-1712

Showing the most recent 10 out of 25 publications